Cytek Biosciences (NASDAQ:CTKB - Get Free Report) declared that its board has approved a share buyback program on Monday, December 30th, RTT News reports. The company plans to repurchase $50.00 million in shares. This repurchase authorization permits the company to repurchase up to 5.9% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its shares are undervalued.
Analyst Ratings Changes
Separately, Piper Sandler lifted their price target on Cytek Biosciences from $8.00 to $8.50 and gave the stock an "overweight" rating in a research note on Monday, November 11th.
Get Our Latest Stock Analysis on CTKB
Cytek Biosciences Price Performance
Shares of NASDAQ CTKB traded up $0.16 during mid-day trading on Monday, reaching $6.55. 476,364 shares of the company traded hands, compared to its average volume of 684,404. Cytek Biosciences has a fifty-two week low of $4.66 and a fifty-two week high of $9.33. The firm has a market cap of $843.71 million, a PE ratio of -81.86 and a beta of 1.46. The stock has a fifty day simple moving average of $6.18 and a 200-day simple moving average of $5.79.
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.03. Cytek Biosciences had a negative net margin of 5.05% and a negative return on equity of 2.58%. The firm had revenue of $51.50 million for the quarter, compared to analysts' expectations of $50.63 million. During the same period in the previous year, the company posted ($0.03) EPS. As a group, analysts predict that Cytek Biosciences will post -0.06 EPS for the current fiscal year.
About Cytek Biosciences
(
Get Free Report)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytek Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.
While Cytek Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
